Click for best price
Nonmuscle Invasive Bladder Cancer Therapeutics Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Non-muscle Invasive Bladder Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-muscle Invasive Bladder Cancer Therapeutics. This report contains market size and forecasts of Non-muscle Invasive Bladder Cancer Therapeutics in global, including the following market information:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Intravesical Chemotherapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-muscle Invasive Bladder Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Type, 2022 (%)
Intravesical Chemotherapy
Intravesical Immunotherapy
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospital
Ambulatory Surgery Center
Others
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-muscle Invasive Bladder Cancer Therapeutics, market overview.
Chapter 2: Global Non-muscle Invasive Bladder Cancer Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Non-muscle Invasive Bladder Cancer Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-muscle Invasive Bladder Cancer Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-muscle Invasive Bladder Cancer Therapeutics Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
111 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-muscle Invasive Bladder Cancer Therapeutics Overall Market Size
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2022 VS 2030
2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.2 Top Global Non-muscle Invasive Bladder Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-muscle Invasive Bladder Cancer Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Intravesical Chemotherapy
4.1.3 Intravesical Immunotherapy
4.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Ambulatory Surgery Center
5.1.4 Others
5.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030
6.3.2 US Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030
6.4.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.4 U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.5 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.6 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.4.8 Benelux Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030
6.5.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.5.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.5.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.5.6 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030
6.6.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.6.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030
6.7.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.7.3 Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
6.7.5 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2018-2030
7 Non-muscle Invasive Bladder Cancer Therapeutics Companies Profiles
7.1 F. Hoffmann-La Roche Ltd.
7.1.1 F. Hoffmann-La Roche Ltd. Company Summary
7.1.2 F. Hoffmann-La Roche Ltd. Business Overview
7.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.1.5 F. Hoffmann-La Roche Ltd. Key News & Latest Developments
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Company Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.3 AstraZeneca
7.3.1 AstraZeneca Company Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.3.5 AstraZeneca Key News & Latest Developments
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Company Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Pfizer Inc. Key News & Latest Developments
7.5 GlaxoSmithKline plc.
7.5.1 GlaxoSmithKline plc. Company Summary
7.5.2 GlaxoSmithKline plc. Business Overview
7.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.5.5 GlaxoSmithKline plc. Key News & Latest Developments
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Company Summary
7.6.2 Sanofi S.A. Business Overview
7.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Sanofi S.A. Key News & Latest Developments
7.7 Novartis AG
7.7.1 Novartis AG Company Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Novartis AG Key News & Latest Developments
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Company Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly and Company Key News & Latest Developments
7.9 Merck & Co.
7.9.1 Merck & Co. Company Summary
7.9.2 Merck & Co. Business Overview
7.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Merck & Co. Key News & Latest Developments
7.10 Viventia Bio Inc.
7.10.1 Viventia Bio Inc. Company Summary
7.10.2 Viventia Bio Inc. Business Overview
7.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Viventia Bio Inc. Key News & Latest Developments
7.11 Celgene Corporation
7.11.1 Celgene Corporation Company Summary
7.11.2 Celgene Corporation Business Overview
7.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.11.5 Celgene Corporation Key News & Latest Developments
7.12 Spectrum Pharmaceuticals, Inc.
7.12.1 Spectrum Pharmaceuticals, Inc. Company Summary
7.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
7.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.12.5 Spectrum Pharmaceuticals, Inc. Key News & Latest Developments
7.13 Herantis Pharma Plc.
7.13.1 Herantis Pharma Plc. Company Summary
7.13.2 Herantis Pharma Plc. Business Overview
7.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.13.5 Herantis Pharma Plc. Key News & Latest Developments
7.14 Taris Biomedical LLC
7.14.1 Taris Biomedical LLC Company Summary
7.14.2 Taris Biomedical LLC Business Overview
7.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.14.5 Taris Biomedical LLC Key News & Latest Developments
7.15 Prometic Life Sciences Inc.
7.15.1 Prometic Life Sciences Inc. Company Summary
7.15.2 Prometic Life Sciences Inc. Business Overview
7.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.15.5 Prometic Life Sciences Inc. Key News & Latest Developments
7.16 Telormediz S.A.
7.16.1 Telormediz S.A. Company Summary
7.16.2 Telormediz S.A. Business Overview
7.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.16.5 Telormediz S.A. Key News & Latest Developments
7.17 Heat Biologics
7.17.1 Heat Biologics Company Summary
7.17.2 Heat Biologics Business Overview
7.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.17.5 Heat Biologics Key News & Latest Developments
7.18 Altor BioScience
7.18.1 Altor BioScience Company Summary
7.18.2 Altor BioScience Business Overview
7.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.18.5 Altor BioScience Key News & Latest Developments
7.19 Ferring B.V.
7.19.1 Ferring B.V. Company Summary
7.19.2 Ferring B.V. Business Overview
7.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.19.5 Ferring B.V. Key News & Latest Developments
7.20 Cold Genesys Inc.
7.20.1 Cold Genesys Inc. Company Summary
7.20.2 Cold Genesys Inc. Business Overview
7.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2018-2023)
7.20.5 Cold Genesys Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market
Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. F. Hoffmann-La Roche Ltd. Company Summary
Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Company Summary
Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 36. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol-Myers Squibb Company Key News & Latest Developments
Table 38. AstraZeneca Company Summary
Table 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 40. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. AstraZeneca Key News & Latest Developments
Table 42. Pfizer Inc. Company Summary
Table 43. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 44. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Inc. Key News & Latest Developments
Table 46. GlaxoSmithKline plc. Company Summary
Table 47. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 48. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. GlaxoSmithKline plc. Key News & Latest Developments
Table 50. Sanofi S.A. Company Summary
Table 51. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 52. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Sanofi S.A. Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 56. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis AG Key News & Latest Developments
Table 58. Eli Lilly and Company Company Summary
Table 59. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 60. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Eli Lilly and Company Key News & Latest Developments
Table 62. Merck & Co. Company Summary
Table 63. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 64. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Merck & Co. Key News & Latest Developments
Table 66. Viventia Bio Inc. Company Summary
Table 67. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 68. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Viventia Bio Inc. Key News & Latest Developments
Table 70. Celgene Corporation Company Summary
Table 71. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 72. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 73. Celgene Corporation Key News & Latest Developments
Table 74. Spectrum Pharmaceuticals, Inc. Company Summary
Table 75. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 76. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 77. Spectrum Pharmaceuticals, Inc. Key News & Latest Developments
Table 78. Herantis Pharma Plc. Company Summary
Table 79. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 80. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 81. Herantis Pharma Plc. Key News & Latest Developments
Table 82. Taris Biomedical LLC Company Summary
Table 83. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 84. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 85. Taris Biomedical LLC Key News & Latest Developments
Table 86. Prometic Life Sciences Inc. Company Summary
Table 87. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 88. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 89. Prometic Life Sciences Inc. Key News & Latest Developments
Table 90. Telormediz S.A. Company Summary
Table 91. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 92. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 93. Telormediz S.A. Key News & Latest Developments
Table 94. Heat Biologics Company Summary
Table 95. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 96. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 97. Heat Biologics Key News & Latest Developments
Table 98. Altor BioScience Company Summary
Table 99. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 100. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 101. Altor BioScience Key News & Latest Developments
Table 102. Ferring B.V. Company Summary
Table 103. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 104. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 105. Ferring B.V. Key News & Latest Developments
Table 106. Cold Genesys Inc. Company Summary
Table 107. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 108. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 109. Cold Genesys Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2022
Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
